Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting

被引:20
|
作者
Lacy, CR
Suh, DC
Barone, JA
Bueno, M
Moylan, D
Swartz, C
Kudipudi, RV
Kostis, JB
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Cardiovasc Dis & Hypertens, New Brunswick, NJ 08903 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Dis Management & Clin Outcomes, New Brunswick, NJ 08903 USA
[3] Rutgers State Univ, New Jersey Coll Pharm, Piscataway, NJ USA
关键词
D O I
10.1001/archinte.162.4.468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although lipid-lowering therapy according to the National Cholesterol Education Program guidelines decreases mortality and morbidity in patients with coronary artery disease (CAD), significant undertreatment of hyperlipidemia continues to occur. This study was designed to determine the impact of an intervention targeted at improving the use of lipid-lowering therapy in patients with CAD in the hospital setting. Methods: Cardiac case managers prompted physicians to obtain lipid profiles for patients with CAD who were not receiving lipid-lowering therapy on admission and initiate lipid-lowering therapy for patients with a low-density lipoprotein level of 130 mg/dL (3.37 mmol/L) or higher during hospitalization. The study population comprised 813 patients with CAD admitted for percutaneous transluminal coronary angioplasty, coronary artery by-pass grafting, or myocardial infarction. A retrospective chart review of lipid testing and treatment rates was conducted in 300 patients in the preintervention period, and a prospective review of rates was conducted in 513 patients during the intervention period. Results: The percentage of patients with CAD not receiving lipid-lowering therapy on admission who had fractionated lipid profiles obtained during hospitalization increased from 27% preintervention to 89% during intervention (odds ratio, 18.27; 95% confidence interval, 11.61-28.74 P<.001). The percentage of patients with a low-density lipoprotein level of 130 mg/dL or higher for whom lipid-lowering therapy was initiated during hospitalization increased from 17% preintervention to 82% during intervention (odds ratio, 24.50; 95% confidence interval, 7.33-81.83 P<.001). Conclusions: The intervention provided by specialized cardiac case managers significantly increased physicians' adherence to the National Cholesterol Education Program treatment guidelines. The results of the present study suggest that intervention programs of this nature could produce a significant positive impact on cardiovascular outcomes if implemented nationally.
引用
收藏
页码:468 / 473
页数:6
相关论文
共 50 条
  • [21] Targeted Strategy in Lipid-Lowering Therapy
    Dayar, Ezgi
    Pechanova, Olga
    BIOMEDICINES, 2022, 10 (05)
  • [22] The impact of lipid-lowering medications on coronary artery plaque characteristics
    Pulipati, Vishnu Priya
    Alenghat, Francis J.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 8
  • [23] AGGRESSIVE LIPID-LOWERING THERAPY USING ROSUVASTATIN IMPROVES ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
    Takayama, Tadateru
    Hiro, Takafumi
    Higuchi, Yoshiharu
    Yoda, Shunichi
    Kunimoto, Satoshi
    Yajima, Yoshiharu
    Hirayama, Atsushi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1630 - A1630
  • [24] Impact of daily glucose fluctuation on progression of luminal narrowing in stable coronary artery disease patients pretreated with lipid-lowering therapy
    Yamamoto, H.
    Shinke, T.
    Otake, H.
    Takaya, T.
    Kuroda, M.
    Takahashi, H.
    Toba, Y.
    Terashita, D.
    Kuroda, K.
    Tahara, N.
    Uzu, K.
    Shinkura, Y.
    Nagasawa, Y.
    Hirata, K.
    EUROPEAN HEART JOURNAL, 2016, 37 : 389 - 389
  • [25] Lipid-lowering therapy after coronary artery bypass grafting: Time for more aggressive intervention
    Lucas, BD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (21) : 2101 - 2103
  • [26] Secondary prevention of coronary artery disease with lipid-lowering drugs
    Delahaye, F
    De Gevigney, G
    ANNALES DE MEDECINE INTERNE, 2001, 152 (03): : 184 - 187
  • [27] The impact of lipid lowering in coronary artery disease
    Goldberg, AC
    CURRENT OPINION IN CARDIOLOGY, 1997, 12 (05) : 488 - 493
  • [28] The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention
    Ma, JM
    Jackevicius, CA
    Dzavik, V
    CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (05) : 419 - 423
  • [29] CORONARY ARTERY CALCIUM IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA RECEIVING STANDARD LIPID-LOWERING THERAPY
    Sheth, Samip
    Rader, Daniel
    Jacoby, Douglas
    CLINICAL CARDIOLOGY, 2019, 42 : S39 - S39
  • [30] Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillator implants
    De Sutter, J. H. A. J.
    De Bacquer, G.
    Jordaens, L.
    De Buyzere, M.
    Matthys, K.
    De Backer, G.
    Tavernier, R.
    EUROPEAN HEART JOURNAL, 2006, 27 : 946 - 946